Urine Cytology Reporting Systems and Standardization
Standardised reporting systems translate cytologic observations into a small set of reproducible diagnostic categories, each linked to an estimated risk of malignancy. In urinary cytology the dominant framework is The Paris System for Reporting Urinary Cytology, which reorganised the field around the reliable detection of high-grade urothelial carcinoma.
Definition
A urine cytology reporting system is a standardised classification that assigns specimens to defined diagnostic categories — from negative through atypical to suspicious and positive for high-grade urothelial carcinoma — to improve reproducibility and convey an estimated risk of malignancy.
Scope
This entry covers the rationale for standardised reporting, the diagnostic categories of The Paris System and their associated risk of malignancy, the principle of anchoring reporting on high-grade disease, and the evolution from the first to the second edition. It is a reference and educational topic and provides no clinical management guidance.
Core questions
- Why did urinary cytology need a standardised reporting system?
- What are the diagnostic categories of The Paris System?
- How is each category linked to a risk of malignancy?
- How did the second edition revise the first?
Key concepts
- Standardised diagnostic categories
- Risk of malignancy stratification
- High-grade-focused reporting
- Atypical urothelial cells category
- Suspicious for high-grade urothelial carcinoma
- Reproducibility and interobserver agreement
- Adequacy criteria
Mechanisms
The Paris System defines categories — non-diagnostic/unsatisfactory, negative for high-grade urothelial carcinoma, atypical urothelial cells, suspicious for high-grade urothelial carcinoma, high-grade urothelial carcinoma, low-grade urothelial neoplasia, and other malignancies — each with morphologic criteria centred on the nuclear-to-cytoplasmic ratio and nuclear features. By deliberately anchoring on high-grade carcinoma, where cytology is most reliable, the system improves interobserver reproducibility and allows each category to be paired with a meta-analytically estimated risk of malignancy that informs interpretation (kurtycz-2020; nikas-2022).
Clinical relevance
Standardised categories communicate diagnostic certainty and an estimated risk of malignancy to clinicians in a consistent vocabulary; this supports interpretation of reports and describes how cytologic evidence is conveyed rather than prescribing individual care. The content is educational only.
Epidemiology
Meta-analyses pooling studies that applied The Paris System report risk-of-malignancy estimates that rise across the categories from negative to positive, providing the quantitative basis for category-based interpretation (nikas-2022).
Evidence & guidelines
The Paris System for Reporting Urinary Cytology was published in 2016 and revised as a second edition in 2022; its categories, adequacy criteria, and high-grade focus constitute the contemporary standard, supported by meta-analytic risk-of-malignancy data and historical accounts of its development (kurtycz-2020; nikas-2022; pambuccian-2022-history).
History
Before The Paris System, urinary cytology terminology varied widely between laboratories, undermining comparability. An international working group introduced The Paris System in 2016 to standardise reporting around high-grade disease, and a second edition followed in 2022 refining categories and criteria (pambuccian-2022-history; kurtycz-2020).
Debates
- How should the atypical category be defined to limit overuse?
- The 'atypical urothelial cells' category has a variable risk of malignancy and is prone to overuse; refining its criteria to improve reproducibility while preserving sensitivity is an ongoing focus across editions.
Key figures
- Dorothy Rosenthal
- Eva Wojcik
- Christopher VandenBussche
- Güliz Barkan
- Daniel Kurtycz
Related topics
Seminal works
- kurtycz-2020
- nikas-2022
- pambuccian-2022-history
Frequently asked questions
- What is The Paris System for Reporting Urinary Cytology?
- It is an internationally developed standardised reporting framework, first published in 2016 and revised in 2022, that classifies urinary specimens into defined categories anchored on the reliable detection of high-grade urothelial carcinoma.
- Why does the system focus on high-grade disease?
- Cytology detects high-grade urothelial carcinoma reproducibly but performs poorly for low-grade lesions, so anchoring categories on high-grade disease maximises reproducibility and clinical usefulness.